ZYNLONTA and glofitamab show strong efficacy in DLBCL patients. Combination has 89.8% overall response rate and 77.6% complete response rate. LOTIS-7 trial expected to complete enrollment in early 2026. Management cites potential best-in-class outcomes for ZYNLONTA combinations. Company plans to share full results at medical congress by late 2026.
The strong data on ZYNLONTA's efficacy and safety enhances investor confidence, similar to previous successful trial results for ADCs, which have often resulted in price increases.
With enrollment completing in 2026 and full data expected, impacts will unfold over time, akin to past industry patterns where trial completion leads to negotiations and potential approvals.
The ongoing trials and strong efficacy data have notable implications for ADCT’s growth, making this information critical for potential investors and analysts.